Windlas Biotech Limited — PPTs, 21-05-2026: Investor Presentation

Windlas Biotech delivered strong FY26 results with revenue growing 19% YoY to Rs 904 Cr, marking its 13th consecutive quarter of record revenue. Adjusted EBITDA rose 26% to Rs 121 Cr, and Adjusted PAT increased 31% to Rs 83 Cr. EPS reached a post-listing high of Rs 31.60. The Generic Formulations CDMO vertical was a key driver, seeing 20% growth to Rs 664 Cr. Exports surged 40% to Rs 46 Cr, while Trade Generics & Institutional grew 13% to Rs 195 Cr.

Strategic focus includes leading generic formulation CDMO, expanding dosage forms with its new injectable facility, and R&D-led product development for complex generics. Recent milestones include GMP certifications for Plant-4 and Plant-5 (Injectables) from the Philippines, and mechanical completion of Plant-6 for commercialization by H1 FY27. The company generated Rs 105 Cr in cash from operations and is net debt-free with strong liquidity of Rs 251 Cr. Management is optimistic about growth, emphasizing client diversification, operational efficiency, and market reach.